Welcome to the first issue of
the Texas Children’s Cancer Center Clinical Trials
e-Newsletter. This e-Newsletter highlights ongoing studies
for neuroblastoma and is designed to provide you with
information regarding the latest clinical trials available
at Texas Children's Cancer Center.
Neuroblastoma, one of the most
aggressive pediatric malignancies, is a major therapeutic
challenge. Texas Children’s Cancer Center offers
comprehensive treatment for newly-diagnosed patients or
neuroblastoma patients with relapsed disease. Listed below
are a few of our available clinical studies for patients
with newly-diagnosed or relapsed neuroblastoma.
|
| Learn More |
 |
| |
Information from preclinical studies demonstrates efficacy of a new microtubulin inhibitor, ABT-751, in neuroblastoma. This novel drug is given orally for seven days, every three weeks. The goal of this COG study is to determine the effectiveness of ABT-751 in children with neuroblastoma.
ANBL0621: A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Recurrent or Refractory Neuroblastoma
|
| Learn More |
|
At Texas Children’s Cancer Center we are determining the optimal dose of Karenitecin, a member of a novel class of camptothecins, in combination with other active agents in the treatment of neuroblastoma and other solid tumors and brain tumors. This study is only available at Texas Children’s Cancer Center.
A Phase I Trial of Escalating Doses of Karenitecin Plus Cyclophosphamide Administered Intravenously Daily for 5 Consecutive Days in Pediatric Patients with Refractory or Recurrent Solid Tumors
|
| Learn More |
|
Texas Children’s Cancer Center is also involved in a COG Phase II
clinical trial of Pemetrexed, a new anti-folate chemotherapy.
ADVL0525: A Phase II Study of Premetrexed in Children with Recurrent Malignancies
|
| Learn More |
|
|
As members of the National Cancer Institute-sponsored New Advances
for Neuroblastoma Treatment Network (NANT), the Phase I Consortium
and the Children’s Oncology Group (COG), we are able to provide a
large number of study options for our patients.
Click here to learn more about other innovative studies for patients with
neuroblastoma. |
 |
For questions contact
neuroblastoma@txccc.org
|
| |
A major goal of the
Neuroblastoma Program
at Texas Children’s Cancer Center is to improve the survival
rate of children with neuroblastoma while minimizing the
toxicities associated with treatment. Texas Children’s Cancer Center, a joint center of Texas Children’s Hospital and Baylor College of Medicine, is dedicated to providing state-of-the-art comprehensive clinical care for children with neuroblastoma through the integration of laboratory and clinical research. Our approach is to combine cutting-edge molecular research with pre-clinical modeling and translational efforts to rapidly develop novel approaches to treating neuroblastoma. Our aim is to develop and provide cutting-edge therapies for children with this disease that offer a real promise of hope.
To speak to one of our neuroblastoma physicians
or to make a patient referral, call
832-822-4242 or 1-800-226-2379
(1-800-CANCER9).
Some of the members of our Neuroblastoma Program:
|
|
| |
 |
Texas
Children's Cancer Center offers more clinical studies than
any other pediatric cancer center in the U.S. with
over 200 clinical trials.
We provide
treatment options for children with even the rarest types of
cancers. Many of these trials have been developed by our
physician-scientists and are only available at this
institution.
Our clinical trial infrastructure is led by a group of
physician experts in clinical trial implementation,
supported by a dedicated, highly experienced, comprehensive
team of nurses and other medical support staff. We pride
ourselves on maintaining timely, open communication with our
patients and their families and fostering effective
relationships with referring physicians.
Click here for information on other childhood cancer clinical trials available at Texas Children’s Cancer Center.
|
| |
 |
|
Neuroblastoma Clinical Trials
